Effect of IBR2 on cell cycle progression. Panel A: A549b cells were incubated in IBR2 for 3, 4 or 5 d, at which time cell density was determined using alamarBlue and plotted as a percent of untreated controls. Determination of cell cycle distribution was undertaken simultaneously (Panel B): A549b cells were incubated in IBR2 for 24 h, followed by harvesting with trypsin, washing with PBS, and fixing in 70% ethanol. Fixed cells were stained with propidium iodide and analyzed with a flow cytometer (10,00 events). The percent of cells in each of G1, S, and G2/M phases was determined using the curve-fitting program FlowJo. Data are means of 3 separate experiments; error bars, SD. Quantification of enhancement in drug toxicity caused by presence of a second agent. The relative cell density of combination-treated, A549b cells was determined as a percent of the respective control, such that the values for the cells treated with imatinib plus 10 μM IBR2 were normalized to those of the cells treated with 10 μM IBR2 alone. Therefore, each IBR2 treatment appears as 100%. If IBR2 has no effect on inhibition of proliferation caused by the second agent, the 2 dose-response curves overlap. In this example, IBR2 caused a leftward shift in the dose-response of imatinib, meaning that the cells were rendered more sensitive to imatinib by the presence of IBR2. The concentration of imatinib that reduced the final cell density by 50% (IC 50 value) was determined by interpolation. The change in this value was calculated as a percent of the original IC 50 value, and this number was used to generate subsequent figures. It is understood that the choices of "drug" and "enhancing agent" (or "second agent") are arbitrary, and the numbers could be used to indicate that imatinib in fact enhances IBR2 cytotoxicity. IBR2, as well as verapamil and B02, are considered to be the enhancing agent for 2 reasons:
(1) they were tested in combination with many different chemotherapy drugs, and so for purposes of clarity they were designated as the second agent in each of these assays, to facilitate comparisons between experiments; (2) it was observed that in many instances the second agent is able to enhance drug toxicity when the second agent is used at concentrations that are on their own non-toxic. This suggests enhancement of the drug toxicity. Note also that the second agent often has no effect on the drug, in which case the change in IC 50 value is zero, and in some instances the second agent interferes with or antagonizes the toxicity of the drug, in which case the change in IC 50 value is a positive value (for examples see Supplementary Figure 9 ). IBR2 causes an increase in IC 50 value for some drugs, depending on the cell line, indicative of antagonism against the cytotoxic activity. Cultured cells were exposed to drugs as described in the legend of Suppl. Fig 4, and the change in IC 50 value was quantitated as described in Suppl. Fig. 3 . A positive value for the change in IC 50 (i.e., increase in the IC 50 ) is indicative of antagonism. Experiments are of limited number: paclitaxel -A549b and HT-29, n=2 or 3 per point, HN-5a/V15e, n = 1 or 2; irinotecan and melphalan -n = 1 or 2; cisplatin -A549b, n=2, HT-29, 1. The IC 50 values were: for paclitaxel, A549b -3.2 +/-0.3 nM (4), HT-29 -3.8 +/-0.2 nM (4), HN5a/V15e, 27.2 +/-10.5 nM (3); for irinotecan, A549b -2.59 +/-0.05 mM (2), HT-29 -4.63 mM (1); for melphalan, A549b -8.5 +/-1.1 mM (2); for cisplatin, A549b -2.9 +/-0.6 mM (2), HT-29 -2.1 mM (1). 
